Good Evolution of Stage IV Neuroblastoma in
the Absence of Stem Cell Autograft
Volume 1 - Issue 4
Wala Ben Kridis1*, Ines Werda1, Rim Kallel2, Nabil Toumi1, Tahia Boudawara2, Afef Khanfir1 and Mounir Frikha1
-
Author Information
Open or Close
- 1Department of Oncology, Habib Bourguiba Hospital, Tunisia
- 2Department of pathology, Habib Bourguiba Hospital, Tunisia
*Corresponding author:
Wala Ben Kridis, Department of oncology, Habib Bourguiba Hospital, Sfax Tunisia
Received: May 29, 2018; Published: June 11, 2018
DOI: 10.32474/PAPN.2018.01.000119
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Neuroblastoma is a relatively common pediatric pathology of the sympathetic nervous system. The particularity of neuroblastoma
lies in its development from cells whose embryological maturation into adult sympathetic nerve cells or chromaffin cells is
incomplete. In the literature, many cases of spontaneous regression of neuroblastoma have been reported, but the mechanisms
for which they are responsible remain ambiguous. The specificity of our case is the benign evolution of an osteomedullary stage
4 neuroblastoma and its maturation into a ganglioneuroma 6 years after the end of chemotherapy. This transformation depends
on various factors related to the tumor (such as the over expression or not of N-myc, the presence or absence of Treks and their
receptors), the host (the intervention of the immune system) and to other external factors. Being able to induce this differentiation
by not leaving it to chance would be a therapeutic challage and could categorically change the prognosis of neuroblastomas. This
merits a lot of research and studies of various potential future treatments (such as treks inhibitors and retinoid).
Keywords: Neuroblastoma; Ganglioneuroma; Etiopathogeny
Abbrevations: NGF: Nerve Growth Factor; BDNF: Brain Derived Neutrophic Factor; VMA: Vanyl Mandelic Acid; NB: Neuroblastoma.
Abstract|
Introduction|
Case Report|
Discussion|
Conclusion|
References|